CHCamilla Oliveira Hoff

Camilla Oliveira Hoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camilla Oliveira Hoff has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial

    by Camilla O. Hoff, Simon Heeke, Yoshitsugu Mitani, Luana G. de Sousa, Juliana M. Siqueira, Kaiyi Li, Flavia Bonini, Diana Bell, Mario L. Marques-Piubelli, Shiaw-Yih Lin, et al.

    Purpose: The phase II axitinib plus avelumab trial in recurrent/metastatic adenoid cystic carcinoma (ACC) demonstrated favorable response rates and progression-free survival (PFS), leading to its inclusion in National Comprehensive Cancer Network guidelines as the first immunotherapy-based option for ACC. We sought to identify biomarkers predictive of clinical benefit from axitinib plus avelumab. Patients and Methods: Twenty-eight patients with ACC enrolled in the study. Pretreatment tumors underwent whole-exome sequencing, transcriptomic profiling, imaging mass cytometry, and tumor, oral rinse, and stool microbiome characterization using 16S rRNA gene sequencing. Associations with PFS were assessed using the Cox proportional hazards model, incorporating ACC subtype (ACC-I vs. ACC-II) as a covariate. Results: ACC comprises 2 proteogenomically distinct subtypes: aggressive, NOTCH1-activated ACC-I and more indolent ACC-II. Here, the median PFS was 1.8 months for ACC-I versus 11.4 months for ACC-II [hazard ratio (HR), 0.14; P < 0.0001)], representing the first demonstration of subtype-specific clinical trial outcomes in ACC. Clinical benefit was not associated with PD-L1 expression, tumor mutational burden, or recurrent genomic mutations. Instead, improved PFS correlated with the presence of intratumoral Escherichia and gut Bifidobacterium and Akkermansia. Transcriptomic profiling identified a 167-gene immune-enriched signature predictive of PFS benefit with axitinib plus avelumab. This signature also predicted benefit from ipilimumab plus nivolumab but not from regorafenib monotherapy, suggesting its specificity for immunotherapy-based combinations. Conclusions: Clinical trial outcomes with axitinib plus avelumab differ significantly by ACC subtype. Furthermore, the identified 167-gene immune-related signature predicts clinical benefit to immunotherapy-based combinations in ACC. These findings provide a framework for future biomarker-driven trial design and patient stratification strategies for this rare malignancy.


  • Open Access

    Survival outcomes of pulmonary metastasis‐directed local therapy in adenoid cystic carcinoma

    by Camilla O. Hoff, Lei Feng, Flavia Bonini, Luana G. Sousa, Kaiwen Wang, Juliana M. Siqueira, Quynh‐Nhu Nguyen, Adel K. El‐Naggar, Wayne L. Hofstetter, Boris Sepesi, et al.

    Background: Adenoid cystic carcinoma (ACC) frequently has pulmonary metastasis (PM). Given limited systemic therapy options, these metastases are often treated with pulmonary metastasis–directed local therapy (PM‐LT), although with unknown impact on overall survival (OS). This single institution, retrospective cohort study investigated the survival outcomes of PM‐LT versus no PM‐LT in ACC.Methods: ACC patients with at least one PM (≥5 mm) were included. PM‐LT was metastasectomy or radiotherapy. Clinicopathologic characteristics were compared between patients with and without PM‐LT. Primary end point was OS from PM diagnosis, with landmark analysis at 6 months, 1 year, 2 years, and 3 years after metastasis diagnosis, with Cox proportional hazards model multivariate analysis and propensity score matching analysis. Subgroup analysis by ACC histology (solid/nonsolid) was performed.Results: Of 219 included ACC, 119 (54%) had no PM‐LT and 100 (46%) did. PM‐LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001). On univariate analysis, PM‐LT by 6 months, 1 year, and 2 years, but not by 3 years, increased OS. On multivariate analysis, PM‐LT by 6 months (p = .12), 1 year (p = .08), or 3 years (p = .08) did not significantly increase OS, but PM‐LT by 2‐years had a borderline statistically significant association (p = .045). Of the 104 nonsolid ACC, 50 underwent PM‐LT and 54 did not. On univariate and multivariate analysis, PM‐LT did not increase OS at any time point for nonsolid ACC.Conclusion: This is the largest study of survival outcomes of PM‐LT in metastatic ACC. Findings suggest PM‐LT does not increase OS in unselected ACC.


  • Open Access

    Supplementary Figure S2 from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

  • Open Access

    Supplementary Table S1 from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

    Patient Clinical and Pathologic Characteristics

  • Open Access

    Supplementary Data S1 from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

  • Open Access

    Data from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

    Purpose:Outcomes after primary surgery for advanced sinonasal squamous cell carcinoma (SCC) are poor. We tested whether induction chemotherapy (IC) can improve disease control or organ preservation.Patients and Methods:A phase II trial evaluated previously untreated patients with stage II to IV, M0 sinonasal SCC. Patients received IC with docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy (CRT) for responders and surgery with adjuvant radiotherapy or CRT for nonresponders. The primary endpoints were overall response rate and locoregional control. Secondary endpoints included progression-free survival (PFS), overall survival (OS), organ preservation, and treatment toxicity.Results:Of the 31 patients enrolled between 2008 and 2020, 28 were evaluated for efficacy. Disease was T4a, T4b, and N+ in 57%, 21%, and 36% of patients, respectively. The overall response rate was 82.1%; 17.9% of patients had stable disease, and 0% had progressive disease. Grade 3 and 4 adverse events occurred in 54% and 18% of patients, respectively; there were no grade 5 adverse events. The 2-year locoregional control and PFS rates were 64.3% [95% confidence interval (CI), 40.4–77.6) and 52.4% (95% CI, 32.3–69.0), respectively. The median PFS was 25.8 months. The median OS was 47.4 months, with a 2-year OS rate of 69.4% (95% CI, 44.9–80.4). No survival difference was observed between surgery versus CRT (HR, 1.07; 95% CI, 0.9–3.84). Of patients alive at 2 years, 63% achieved organ preservation, avoiding maxillectomy (38%), craniotomy (13%), or orbital exenteration (38%).Conclusions:IC and response-directed local treatment achieved promising disease control and added organ preservation for patients with advanced sinonasal SCC.

  • Open Access

    Supplementary Table S2 from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

    Representativeness of Study Participants

  • Open Access

    Supplementary Figure S1 from Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

  • Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma

    by Kevin J. Contrera, Renata Ferrarotto, Brandon Gunn, Shirley Y. Su, Merrill S. Kies, Bonnie S. Glisson, Adam S. Garden, Dianna Roberts, Curtis Habna, Camilla O. Hoff, et al.

    Purpose: Outcomes after primary surgery for advanced sinonasal squamous cell carcinoma (SCC) are poor. We tested whether induction chemotherapy (IC) can improve disease control or organ preservation. Patients and Methods: A phase II trial evaluated previously untreated patients with stage II to IV, M0 sinonasal SCC. Patients received IC with docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy (CRT) for responders and surgery with adjuvant radiotherapy or CRT for nonresponders. The primary endpoints were overall response rate and locoregional control. Secondary endpoints included progression-free survival (PFS), overall survival (OS), organ preservation, and treatment toxicity. Results: Of the 31 patients enrolled between 2008 and 2020, 28 were evaluated for efficacy. Disease was T4a, T4b, and N+ in 57%, 21%, and 36% of patients, respectively. The overall response rate was 82.1%; 17.9% of patients had stable disease, and 0% had progressive disease. Grade 3 and 4 adverse events occurred in 54% and 18% of patients, respectively; there were no grade 5 adverse events. The 2-year locoregional control and PFS rates were 64.3% [95% confidence interval (CI), 40.4–77.6) and 52.4% (95% CI, 32.3–69.0), respectively. The median PFS was 25.8 months. The median OS was 47.4 months, with a 2-year OS rate of 69.4% (95% CI, 44.9–80.4). No survival difference was observed between surgery versus CRT (HR, 1.07; 95% CI, 0.9–3.84). Of patients alive at 2 years, 63% achieved organ preservation, avoiding maxillectomy (38%), craniotomy (13%), or orbital exenteration (38%). Conclusions: IC and response-directed local treatment achieved promising disease control and added organ preservation for patients with advanced sinonasal SCC.


  • Open Access

    First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report

    by Camilla O. Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana G. de Sousa, Adel K. El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto

    First use of AXL-targeting in adenoid cystic carcinoma (ACC); with positive results, ACC now included in AXL studies.